“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial looking at eribulin and dacarbazine for sarcoma
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial compared the chemotherapy drugs eribulin and dacarbazine for people with soft tissue sarcoma that had come back after treatment.
More about this trial
- if eribulin is better than dacarbazine for people with soft tissue sarcoma that has come back after chemotherapy
- more about the side effects
Summary of results
- half had eribulin
- half had dacarbazine
- 13.5 months for those who had eribulin
- 11.5 months for those who had dacarbazine
How to join a clinical trial
Dr Michael Leahy
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer